Phase 2
Completed N=267
A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease
Source: ClinicalTrials.gov NCT04992065 ↗Enrolled (actual)
267
Serious AEs
4.9%
Results posted
Jun 2025
Primary outcomePrimary: Percentage Change in Low-density Lipoprotein (LDL)-Cholesterol — -27; -41; -55; 6 Percentage change of LDL cholesterol — p=<.0001
Summary
This study looks at how well a new medicine, NNC0385-0434, works to lower blood cholesterol levels. Participants will either get NNC0385-0434 as a tablet (a potential new medicine), or placebo as a tablet (a dummy medicine that looks like NNC0385-0434 but has no effect on the body), or evolocumab as an injection (a medicine that doctors can already prescribe).
Which treatment participants get is decided by chance. If participants get NNC0385-0434 or placebo participants will need to take 1 tablet every morning. If participants get evolocumab participants will need to take 1 injection every 2 weeks.
The study will last for about 22 weeks. About 255 people will participate in the study. Participants will have 9 visits to the clinic and 2 phone calls with the study doctor. Some people will be invited to participate in a sub-study and will have 4 extra visits (13 visits in total). Participants will have blood samples taken at all visits to the clinic (except visit 0). At 4 clinic visits, participants will have an electrocardiogram (ECG). This is a test to check your heart.
Women can only take part in the study if they are not able to become pregnant.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage Change in Low-density Lipoprotein (LDL)-Cholesterol |
-27; -41; -55; 6; -59 | <.0001 sig |
| SECONDARY Percentage Change in Total Cholesterol |
-14; -25; -33; 4; -38 | — |
| SECONDARY Percentage Change in High Density Lipoprotein (HDL)-Cholesterol |
4; 5; 7; 1; 5 | — |
| SECONDARY Percentage Change in Very Low Density Lipoprotein (VLDL)-Cholesterol |
5; -7; -15; 3; -16 | — |
| SECONDARY Percentage Change in Triglycerides |
5; -7; -16; 2; -16 | — |
| SECONDARY Percentage Change in Total Apolipoprotein B (Apo B) |
-20; -34; -48; 6; -52 | — |
| SECONDARY Percentage Change in Total Apolipoprotein CIII (Apo CIII) |
-0; -7; -16; 2; -15 | — |
| SECONDARY Change in Total Lipoprotein(a) (Lp[a]): Ratio to Baseline |
0.79; 0.70; 0.66; 0.99; 0.59 | — |
| SECONDARY Number of Treatment-emergent Adverse Events (TEAEs) |
82; 60; 65; 56; 81 | — |
Eligibility Criteria
Inclusion Criteria
- Males or females of non-childbearing potential.
- Established atherosclerotic cardiovascular disease (ASCVD) (criteria a) or ASCVD risk (criteria b):
- Age 40 years or older at the time of signing informed consent and history of ASCVD
- Age above 50 years at the time of signing informed consent and with ASCVD risk
- Serum LDL-C above or equal to 1.8 mmol/L (above or equal to 70 mg/dL) as measured by the central laboratory at screening.
- Japanese participants: Serum LDL-C above or equal to 2.6 mmol/L (above or equal to 100 mg/dL) for participants of 40 years of age or older and with a history of coronary heart disease, and serum LDL-C above or equal to 3.1 mmol/L (above or equal to 120 mg/dL) for all other Japanese participants
- Participants must be on maximally tolerated dose of statins.
- Participants not receiving statin must have documented evidence of intolerance to all doses of at least two different statins.
Exclusion Criteria
- Treatment with PCSK9i therapy (alirocumab or evolocumab within 90 days prior to screening) or PCSK9 siRNA therapy (inclisiran within 12 months prior to screening).
- Fasting triglyceride above 4.52 mmol/L (above 400 mg/dL) as measured by the central laboratory at screening.
- Myocardial infarction, stroke, hospitalization for unstable angina pectoris or transient ischaemic attack within 180 days prior to the day of screening.
- Renal impairment with eGFR less than 30 ml/min/1.73 m2 as measured by the central laboratory at screening
Data sourced from ClinicalTrials.gov (NCT04992065). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.